Terms: = Ovarian cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
135 results:
1. Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and ovarian cancer, Cologne.
Kast K; Rhiem K; Larsen M; Wappenschmidt B; Schmutzler R
Cancer Med; 2024 Feb; 13(3):e6920. PubMed ID: 38230850
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell profiling identifies distinct hormonal, immunologic, and inflammatory signatures of endometriosis-constituting cells.
Shin S; Chung YJ; Moon SW; Choi EJ; Kim MR; Chung YJ; Lee SH
J Pathol; 2023 Nov; 261(3):323-334. PubMed ID: 37807404
[TBL] [Abstract] [Full Text] [Related]
3. MicroRNA-592 Inhibits the Growth of ovarian cancer Cells by Targeting erbb3.
Jin Q; Zhang N; Zhan Y; Xu X; Han C; Zhao H; Hu X; Tang H; Wu Y
Technol Cancer Res Treat; 2023; 22():15330338231157156. PubMed ID: 36916303
[No Abstract] [Full Text] [Related]
4. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and her3 immunohistochemical analysis.
Inaki K; Shibutani T; Maeda N; Eppenberger-Castori S; Nicolet S; Kaneda Y; Koyama K; Qiu Y; Wakita K; Murakami M
PLoS One; 2022; 17(9):e0274140. PubMed ID: 36137139
[TBL] [Abstract] [Full Text] [Related]
5. PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis.
Sohn EJ
BMC Cancer; 2022 Jun; 22(1):708. PubMed ID: 35761259
[TBL] [Abstract] [Full Text] [Related]
6. ROS and miRNA Dysregulation in ovarian cancer Development, Angiogenesis and Therapeutic Resistance.
Stieg DC; Wang Y; Liu LZ; Jiang BH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743145
[TBL] [Abstract] [Full Text] [Related]
7. Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.
Ma Y; Qi B; Ning M; Zhang L; An Z; Zhao J
Eur Biophys J; 2022 Apr; 51(3):283-295. PubMed ID: 35307752
[TBL] [Abstract] [Full Text] [Related]
8. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.
Ross DS; Devereaux KA; Jin C; Lin DY; Zhang Y; Marra A; Makker V; Weigelt B; Ellenson LH; Chui MH
Mod Pathol; 2022 Jul; 35(7):962-971. PubMed ID: 34972830
[TBL] [Abstract] [Full Text] [Related]
9. NOX4 Signaling Mediates cancer Development and Therapeutic Resistance through her3 in ovarian cancer Cells.
Liu WJ; Huang YX; Wang W; Zhang Y; Liu BJ; Qiu JG; Jiang BH; Liu LZ
Cells; 2021 Jun; 10(7):. PubMed ID: 34209278
[TBL] [Abstract] [Full Text] [Related]
10. The Anti-her3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy.
Gutsch D; Jenke R; Büch T; Aigner A
Cells; 2021 Jan; 10(2):. PubMed ID: 33572976
[TBL] [Abstract] [Full Text] [Related]
12. LncRNA HOTAIR regulates anoikis-resistance capacity and spheroid formation of ovarian cancer cells by recruiting EZH2 and influencing H3K27 methylation.
Dai ZY; Jin SM; Luo HQ; Leng HL; Fang JD
Neoplasma; 2021 May; 68(3):509-518. PubMed ID: 33502891
[TBL] [Abstract] [Full Text] [Related]
13. Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
Lee DW; Lee W; Kwon M; Lee HN
Oncol Rep; 2021 Jan; 45(1):390-400. PubMed ID: 33200225
[TBL] [Abstract] [Full Text] [Related]
14. NRG1/erbb3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract] [Full Text] [Related]
15. Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking.
Lanotte R; Garambois V; Gaborit N; Larbouret C; Musnier A; Martineau P; Pèlegrin A; Chardès T
Cancer Sci; 2020 Jul; 111(7):2508-2525. PubMed ID: 32415868
[TBL] [Abstract] [Full Text] [Related]
16. erbb3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
Chen C; Gupta P; Parashar D; Nair GG; George J; Geethadevi A; Wang W; Tsaih SW; Bradley W; Ramchandran R; Rader JS; Chaluvally-Raghavan P; Pradeep S
Oncogene; 2020 Apr; 39(14):2921-2933. PubMed ID: 32029900
[TBL] [Abstract] [Full Text] [Related]
17. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
Solsky I; Chen J; Rebbeck TR
Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
[TBL] [Abstract] [Full Text] [Related]
18. Heterogeneous alteration of the erbb3-MYC axis associated with MEK inhibitor resistance in a
Colombo I; Garg S; Danesh A; Bruce J; Shaw P; Tan Q; Quevedo R; Braunstein M; Oza AM; Pugh T; Lheureux S
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31836588
[TBL] [Abstract] [Full Text] [Related]
19. Dual targeting of IGF-1R and erbb3 as a potential therapeutic regimen for ovarian cancer.
Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
[TBL] [Abstract] [Full Text] [Related]
20. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (her3) mRNA-expressing platinum-resistant ovarian cancer.
Lorusso D; Hilpert F; González Martin A; Rau J; Ottevanger P; Greimel E; Lück HJ; Selle F; Colombo N; Kroep JR; Mirza MR; Berger R; Pardo B; Grischke EM; Berton-Rigaud D; Martinez-Garcia J; Vergote I; Redondo A; Cardona A; Bastière-Truchot L; du Bois A; Kurzeder C;
Int J Gynecol Cancer; 2019 Sep; 29(7):1141-1147. PubMed ID: 31420414
[TBL] [Abstract] [Full Text] [Related]
[Next]
